Nocturia Therapeutic Pipeline Key Players and Drugs Review H1 2015 Market Research Report

DALLAS, March 25, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Nocturia - Pipeline Review, H1 2015" therapeutic market research report provides an overview of the Nocturia's therapeutic pipeline.

The report "Nocturia - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Nocturia. Nocturia can be defined as the need to wake and pass urine at night. Nocturia can be normal and more common with aging. Nocturia can also be a sign of an underlying condition, such as diabetes or urinary infection. Nocturia is often a symptom of other medical conditions including urological infection, a tumor of the bladder or prostate, bladder prolapse, or disorders affecting sphincter control. Drinking too much fluid during the evening can cause to urinate more often during the night. Caffeine and alcohol after dinner can also lead to this problem.

This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nocturia and special features on late-stage and discontinued projects.

Companies discussed in this report include:

• Allergan, Inc.
• Ferring International Center S.A.
• Sumitomo Dainippon Pharma Co., Ltd.
• Vantia Therapeutics

Drug Profiles discussed in this report include afacifenacin, ASP-7035, desmopressin acetate, FE-999309, fedovapagon, Paxerol. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310168 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this report includes: Feb 02, 2010: Vantia Therapeutics Initiates Phase IIb Clinical Trial of VA106483 for Nocturia; Jun 29, 2009: Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-Diuretic Effect In Phase IIa Trial In Nocturia; Mar 24, 2009: Vantia Therapeutics' VA106483 Completes Phase IIa Trial.

The scope of the report ranges from global therapeutic landscape of Nocturia to the recent news and deals undertaken in the field of pipeline review. There is a detailed assessment of monotherapy and combination therapy pipeline projects along with a products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The person referring to the report will be able to devise his R&D development strategies as it includes significant competitor information, analysis and valuable insights. The report mentions the new entrants to the market and the emerging players. The report also helps in developing and designing in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Nocturia
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Nocturia pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics .

More reports on Oral Therapeutics:

Coronavirus Infection - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Coronavirus Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include AstraZeneca PLC, Hemispherx Biopharma, Inc., Humabs BioMed SA, Inovio Pharmaceuticals, Inc., NanoViricides, Inc., Novavax, Inc. Complete report available at http://www.rnrmarketresearch.com/coronavirus-infection-pipeline-review-h1-2015-market-report.html .

Germ Cell Tumors - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Germ Cell Tumors. The report reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include ArQule, Inc., Novartis AG, Philogen S.p.A., Tolero Pharmaceuticals, Inc. Complete report available at http://www.rnrmarketresearch.com/germ-cell-tumors-pipeline-review-h1-2015-market-report.html .

Left Ventricular Dysfunction - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Left Ventricular Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Acorda Therapeutics, Inc., Amgen Inc., Innopharmax Inc., RedHill Biopharma Ltd. Complete report available at http://www.rnrmarketresearch.com/left-ventricular-dysfunction-pipeline-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

SOURCE RnR Market Research